Merck (MRK) and Ridgeback Biotherapeutics announced that the former has submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for an orally administered drug, molnupiravir, to treat COVID-19. The application has been made based on positive results from a Phase 3 MOVe-OUT clinical trial, which reveals that molnupiravir, if administered to non-hospitalized adult patients with mild-to-moderate COVID-19, reduces the risk of progressing to a severe case and hospitalization. (See Merck stock charts on TipRanks) The interim analysis shows that molnupiravir reduces the risk of hospitalization or death by about 50%. About 7.
https://www.tipranks.com/news/merck-submits-eua-application-for-oral-antiviral-drug?utm_source=advfn.com&utm_medium=referral
Merck (NYSE:MRK)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more Merck Charts.